<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043288</url>
  </required_header>
  <id_info>
    <org_study_id>NC-6004-005</org_study_id>
    <nct_id>NCT02043288</nct_id>
  </id_info>
  <brief_title>Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer</brief_title>
  <official_title>A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orient Europharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NanoCarrier Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Orient Europharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is designed to evaluate the impact of the addition of NC-6004 to
      gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic
      cancer in Asian countries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is one of the most deadly cancers because of the predominately late
      diagnosis. Gemcitabine (GEM) is the standard treatment for advanced and metastatic pancreatic
      cancer. According to preclinical data and few early phase studies, a combined use of
      gemcitabine and cisplatin (CDDP) showed synergistic efficacy against pancreatic cancer.
      NC-6004, a novel micellar cisplatin formulation, retains the activity but avoids the renal
      toxicity and neurotoxicity caused by the high peak Cmax concentrations of cisplatin. This
      trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the
      treatment of patients with locally advanced or metastatic pancreatic cancer.

      The main hypothesis of this study is that NC-6004 plus gemcitabine combination is superior to
      gemcitabine alone in terms of overall survival in locally advanced or metastatic pancreatic
      cancer patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3.5 years</time_frame>
    <description>Overall survival is defined as the time from the treatment initiation until death from any cause, and censored at the last follow up time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>3.5 years</time_frame>
    <description>Progression free survival is defined as the time from the treatment initiation until progression or death, and censored at the last follow up time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR) and disease control rate (DCR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria</measure>
    <time_frame>3.5 years</time_frame>
    <description>Response rate is defined as counts and proportions of patients responding complete response or partial response within the duration of the study.
Disease control rate is defined as counts and proportions of patients responding complete response, partial response or progressive disease within the duration of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>3.5 years</time_frame>
    <description>Duration of overall response (DOR) will be measured from the time of initial response (CR or PR) until documented progression or death, and censored at last follow up time.
Duration of stable disease (DSD) will be measured from the time of initial stable disease (SD) until documented progression or death, and censored at last follow up time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA19-9</measure>
    <time_frame>3.5 years</time_frame>
    <description>CA19-9 values and changes from baseline will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) using EORTC QLQ-C30</measure>
    <time_frame>3.5 years</time_frame>
    <description>Quality of life (QoL) values and changes from baseline will be summarized.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>NC-6004 and Gemcitabine combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NC-6004 90mg/m2 i.v. on Day 1 and Gemcitabine 1000mg/m2 i.v. on Day 1 and Day 8 respectively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine 1000mg/m2 i.v. on Day 1 ,8 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NC-6004</intervention_name>
    <description>Study group (3 week/cycle):
NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1</description>
    <arm_group_label>NC-6004 and Gemcitabine combination</arm_group_label>
    <other_name>Micelplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Study group (3 week/cycle):
Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)
Control group (4 week/cycle):
Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15</description>
    <arm_group_label>Gemcitabine monotherapy</arm_group_label>
    <arm_group_label>NC-6004 and Gemcitabine combination</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female aged between 20 to 80 years (inclusive)

          2. Unresectable, histologically or cytologically confirmed, locally advanced or
             metastatic pancreatic cancer (adenocarcinoma, adenosquamous carcinoma or poorly
             differentiated carcinoma)

          3. Presence of at least one measurable tumor lesion (longest diameter ≥ 10 mm)

          4. No prior systemic anti-cancer therapy* and radiotherapy** for advanced pancreatic
             cancer

             * Patients with post-operative adjuvant chemotherapy other than platinum products
             (e.g. cisplatin, carboplatin and oxaliplatin, etc.) or radiotherapy or
             chemo-radiotherapy completed more than 6 months before recurrence will be eligible.

             ** Patients with prior palliative radiotherapy of &lt; 20% bone marrow involvement prior
             to 6 months from screening will be eligible.

          5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1

          6. Adequate organ function defined as:

               -  3,000 cells/μL ≤ WBC ≤ 12,000 cells/μL

               -  Absolute neutrophils count (ANC) ≥ 1,500 cells/μL

               -  Platelets ≥ 100,000 cells/μL

               -  Hemoglobin (Hb) ≥ 9.0 g/dL

               -  Alanine amino transferase (ALT) and aspartate amino transferase (AST) ≤ 2.5 times
                  the upper limit of normal (ULN) in patients with no demonstrable hepatic
                  metastasis, or ≤ 5 x ULN in patients with hepatic metastasis

               -  Serum bilirubin ≤ 1.5 x ULN in patients with no demonstrable hepatic metastasis
                  and obstructive jaundice, or ≤ 2.5 x ULN in patients with hepatic metastasis or
                  obstructive jaundice

               -  Serum creatinine (SCr) ≤ 1.5 mg/dL and creatinine clearance (CrCl) ≥ 60 mL/min
                  (from 24-hour urine test or Cockcroft-Gault formula)

               -  Corrected serum calcium ≤ ULN

          7. If fertile*, willing to use barrier contraception till 6 months after the end of
             treatment

             * With the following exceptions: 1) pre-menopausal females with bilateral tubal
             ligation, bilateral oophorectomy or hysterectomy; 2) post-menopausal women, defined as
             12 months of spontaneous amenorrhea; 3) males with vasectomy.

          8. Willing and able to comply with study procedures and provide written informed consent

        Exclusion criteria:

          1. Pregnancy or breastfeeding

          2. Active concomitant malignancy or history of other cancer except carcinoma in situ of
             cervical squamous cell carcinoma, stage I colon cancer or other malignance that has
             remained disease-free for more than 3 years after curative intervention

          3. Metastasis to the central nervous system or brain

          4. Evidence of hearing impaired ≥ Grade 2 as assessed by pure tone audiometry or other
             neurotoxicity ≥ Grade 2

             * Patients with age-associated hearing loss at the high frequencies that, in the
             judgment of the investigator, would not interfere significantly with patient's safety
             or study assessments will be eligible to enroll.

          5. Patient with pulmonary fibrosis or interstitial pneumonia

          6. Marked pleural effusion or ascites above Grade 2

          7. Patient with known HIV infection

          8. Patient with active hepatitis B, hepatitis C or any other ongoing severe infections

          9. Patient with severe mental disorder

         10. As judged by the investigator, any evidence of significant laboratory findings or
             severe/uncontrolled clinical disorders (e.g. dementia, myocardial infarction within 6
             months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart
             failure, unstable angina, active cardiomyopathy, unstable arrhythmia, and other
             unstable or uncompensated respiratory, cardiac, hepatic, renal and/or infectious
             disease)

         11. Patient with known hypersensitivity to Pt compounds

         12. Known severe drug hypersensitivity

         13. Treatment with a non-approved or investigational product within 30 days before Day 1
             of study treatment

         14. Alcoholic liver disease* or liver disease with obvious clinical symptom or sign

             * the investigator should judge from medical examination by interview and laboratory
             test including γ-GTP, AST and ALT

         15. Daily Alcohol consumption within 6 months before the screening as an average weekly
             intake of &gt;21 units (168 g of pure alcohol) or an average daily intake of &gt;3 units (24
             g of pure alcohol) for males / an average weekly intake of &gt;14 units (112 g of pure
             alcohol) or an average daily intake of &gt;2 units (16 g of pure alcohol) for females.

             Kind of Alcohol Alcohol Percentage mL per 1 unit =8 g of pure alcohol

             Beer 5 % 200 mL

             Whiskey/Brandy 40 % 25 mL

             Wine 12 % approx. 83 mL

             Sake 15 % approx. 67 mL

             Distilled spirit 25 % 40 mL

             Kaoliang 50 % 20 mL

         16. Patient with uncontrolled diabetes

         17. Radiotherapy within 6 months before screening

         18. Experienced Abdominal Radiotherapy

         19. Experienced treatment of Gemtuzumab ozogamicin

         20. Patient with autoimmune hepatitis or idiopathic thrombocytopenic purpura (ITP)

         21. Observation of &quot;attenuated or reversed hepatic venous portal blood flow*&quot; was
             confirmed by doppler ultrasonography or CT (recommend evaluation in arterial phase,
             portal-venous phase and equilibrium phase) of the liver * On doppler ultrasonography
             of right and left branch of portal vein, blood flow is measured as about 0 mL/min or
             between plus and minus, which indicate obvious blood flow obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Tzong Chen, M.D., Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Cancer Research, National Health Research Institutes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Shikokuchūō</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Hospital of the National Center for Global Health and Medicine</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyorin university Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital (AUH)</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center (SMC)</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital (CUK SSMH)</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital (KUGH)</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>50-1</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sultan Ismail</name>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makati Medical Center</name>
      <address>
        <city>Makati</city>
        <zip>1229</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiayi Chang Gung Memorial Hospital</name>
      <address>
        <city>Chiayi City</city>
        <zip>61363</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Kaohsiung Branch</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40750</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>106</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koo Foundation Sun Yat-Sen Cancer Center</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University-Shuang-Ho Hospital, Ministry of Health and Welfare</name>
      <address>
        <city>Taipei</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Linkou Branch</name>
      <address>
        <city>Taipei</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Yongkang</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Platinum</keyword>
  <keyword>Micelle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

